Drug interactions of directly acting antivirals in the treatment of chronic virus hepatitis C
In recent years, in Russia epidemic situation on the VCH becomes apparent. Increase in morbidity of chronic hepatitis C (CHC) from 31.8 cases per 100 000 in 2005 to 39.9 per 100 000 in 2011 is observed; VHC often affects young persons, with a high Level of chronization and such possible outcomes as cirrhosis and primary liver cancer. The processes at key stages of hepatitis C virus life cycle are the main targets in the development of drugs for the treatment of chronic hepatitis C. The treatment is indicated for patients with hepatitis C with compensated and decompensated chronic liver disease, previously treated or not to receiving treatment, ready to receive therapy and with no contraindications. Through to 2011, the combination of pegylated interferon (PegIFN)-α and ribavirin for 24 or 48 weeks was officially recommended CHC treatment. After approval of three new DAAs for the treatment of CHC in Europe in 2014, wide interferon-free treatment regimens come into common use. These schemes have been used mainly for the treatment of patients with severe liver damage (stage 3-4 liver fibrosis according METAVIR scale (F3, F4)). Combination of drugs requires careful use and dose adjustment, alternation in drug intake time, and additional monitoring. Drug interactions should be especially considered when choosing a combination therapy in HCV and HIV co-infection.